“Arcane paper-driven processes in cell collection, therapeutic production and logistical delivery, have not kept pace with medical and digital innovation and can limit their potential,” the firm said.
CEO Amy Du Ross told us increased production of gene and cell therapies prompted the software’s development.
“Until now, most of these processes have been siloed and paper-driven because the therapies have been in clinical trial phase, and hence at limited production volumes,” she said.
“Now that we are poised to drive production and delivery at scale, the need for our software and analytics platform has come forward,” she added.
Du Ross said the platform, which addresses the end-to-end cell and gene therapy process, will improve patient access, accelerate treatment delivery, and promote safety and regulatory compliance.
The technology was funded by investors including Vineti co-founders GE Ventures and Mayo Clinic Ventures.
Du Ross told us the platform will benefit drug manufacturers via its traceability features, which track patient cells in order to match treatments with the correct patients.
“The Vineti cloud platform solution is comprised of a suite of software applications focused around chain of identity and custody, supply chain orchestration, treatment ordering and scheduling, point-of-care GMP procedures, and reimbursement,” she said.
“We seek to standardise – and so, industrialise – the key process and delivery considerations across the entire value chain,” she said.
The software will also accelerate manufacturers’ time to market, by complying with regulatory standards, she added.